Jaeger Beate Roxane, Arron Hayley Emma, Kalka-Moll Wiltrud M, Seidel Dietrich
Lipidzentrum Nordrhein, Mülheim, Germany.
Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa.
Front Cardiovasc Med. 2022 Oct 11;9:1007636. doi: 10.3389/fcvm.2022.1007636. eCollection 2022.
Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capillaries show inflammatory and procoagulatory activation with cell necrosis, thrombi, and massive fibrinoid deposits, namely, unsolvable microthrombi, which results in an obstructed gas exchange. Heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.) apheresis solves these problems by helping the entire macro- and microcirculation extracorporeally. It uses unfractionated heparin, which binds the spike protein and thereby should remove the virus (debris). It dissolves the forming microthrombi without bleeding risk. It removes large amounts of fibrinogen (coagulation protein), which immediately improves the oxygen supply in the capillaries. In addition, it removes the precursors of both the procoagulatory and the fibrinolytic cascade, thus de-escalating the entire hemostaseological system. It increases myocardial, cerebral, and pulmonary blood flow rates, and coronary flow reserve, facilitating oxygen exchange in the capillaries, without bleeding risks. Another factor in COVID is the "cytokine storm" harming microcirculation in the lungs and other organs. Intervention by H.E.L.P. apheresis could prevent uncontrollable coagulation and inflammatory activity by removing cytokines such as interleukin (IL)-6, IL-8, and TNF-α, and reduces C-reactive protein, and eliminating endo- and ecto-toxins, without touching protective IgM/IgG antibodies, leukocyte, or platelet function. The therapy can be used safely in combination with antiviral drugs, antibiotics, anticoagulants, or antihypertensive drugs. Long-term clinical experience with H.E.L.P. apheresis shows it cannot inflict harm upon patients with COVID-19.
患有长期新冠和急性新冠的患者应能从使用H.E.L.P.血液成分分离术治疗中获益,该疗法已临床应用37年。新冠病毒病可导致严重的急性多器官疾病,随后,在许多患者中会出现慢性疾病——长期新冠/新冠后综合征(PASC)。肺泡组织和相邻毛细血管表现出炎症和促凝激活,伴有细胞坏死、血栓和大量纤维蛋白样沉积物,即无法溶解的微血栓,这导致气体交换受阻。肝素诱导的体外低密度脂蛋白/纤维蛋白原沉淀(H.E.L.P.)血液成分分离术通过体外辅助整个大循环和微循环来解决这些问题。它使用普通肝素,这种肝素会结合刺突蛋白,从而应该能够清除病毒(碎片)。它能溶解正在形成的微血栓且无出血风险。它能清除大量纤维蛋白原(凝血蛋白),这会立即改善毛细血管中的氧气供应。此外,它能清除促凝和纤溶级联反应的前体,从而使整个止血系统的活动减弱。它能提高心肌、脑和肺的血流速度以及冠状动脉血流储备,促进毛细血管中的氧气交换,且无出血风险。新冠中的另一个因素是“细胞因子风暴”,它会损害肺部和其他器官的微循环。H.E.L.P.血液成分分离术的干预可通过清除白细胞介素(IL)-6、IL-8和肿瘤坏死因子-α等细胞因子来预防无法控制的凝血和炎症活动,降低C反应蛋白,并清除内毒素和外毒素,同时不影响保护性IgM/IgG抗体、白细胞或血小板功能。该疗法可安全地与抗病毒药物、抗生素、抗凝剂或降压药物联合使用。H.E.L.P.血液成分分离术的长期临床经验表明,它不会对新冠病毒病患者造成伤害。